Shots:
The P-IIb (LUMA) study evaluates the efficacy and safety of BIIB122 (DNL151) vs PBO in ~640 patients aged b/w 30 & 80yrs. with early-stage PD. The therapy was discovered and developed by Denali
The 1EPs of the study are time to confirm worsening in MDS-UPDRS parts II & III combined score over the treatment period. The P-IIb (LUMA) & P-III (LIGHTHOUSE) studies in patients with PD caused by LRRK2 pathogenic mutations are part of the BIIB122 clinical development program
BIIB122 is a selective, central nervous system-penetrant small molecule inhibitor of LRRK2 that is hypothesized to improve lysosomal dysfunction. The P-III (LIGHTHOUSE) study is expected to initiate in 2022
Ref:Biogen | Image: Biogen
